Augmedix, Inc.

AUGX

US05105P1075

Business Support Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.85 ^USD	+2.15%		-4.68%	-51.28%

Apr. 24	Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments	CI
Apr. 12	Augmedix Insider Sold Shares Worth $369,285, According to a Recent SEC Filing	MT

Augmedix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 18, 2024 at 04:02 pm EDT

Augmedix, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 12.68 million compared to USD 8.75 million a year ago. Net loss was USD 4.49 million compared to USD 5.6 million a year ago.

Latest news about Augmedix, Inc.

Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments	Apr. 24	CI
Augmedix Insider Sold Shares Worth $369,285, According to a Recent SEC Filing	Apr. 12	MT
North American Morning Briefing : Traders Await -2-	Apr. 10	DJ
Augmedix, Inc. Integrates with Andor Health to Revolutionize Ambient Clinical Documentation for Ambulatory Virtual Care	Apr. 09	CI
Augmedix Insider Sold Shares Worth $454,454, According to a Recent SEC Filing	Apr. 05	MT
Augmedix Insider Sold Shares Worth $380,108, According to a Recent SEC Filing	Apr. 04	MT
Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide	Apr. 04	CI
Top Midday Gainers	Mar. 19	MT
Evercore ISI Adjusts Price Target on Augmedix to $4.50 From $6.50, Maintains In-Line Rating	Mar. 19	MT
Augmedix Shares Surge 15% Premarket Tuesday as Revenue Growth Beats Expectations, Gross Margins Expand in Q4	Mar. 19	MT
Transcript : Augmedix, Inc., Q4 2023 Earnings Call, Mar 18, 2024	Mar. 18
Earnings Flash (AUGX) AUGMEDIX Reports Q4 Revenue $12.7M, vs. Street Est of $12.4M	Mar. 18	MT
Augmedix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Augmedix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Augmedix Provides Revenue Guidance for the Year 2024	Mar. 18	CI
Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go	Mar. 12	CI
Certain Restricted Stock Units of Augmedix, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2024.	Feb. 13	CI
Certain Stock Options of Augmedix, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2024.	Feb. 13	CI
Certain Common Stock of Augmedix, Inc. are subject to a Lock-Up Agreement Ending on 14-FEB-2024.	Feb. 13	CI
Augmedix Names Tomer Levy as New Senior Vice President of Engineering	Feb. 13	CI
Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023	Jan. 05	CI
Evercore ISI Initiates Augmedix With In Line Rating, Price Target is $6	Dec. 15	MT
Waning Optimism on Rate Hike Pause, Cisco Fall Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday	Nov. 16	MT
Top Premarket Decliners	Nov. 16	MT
Augmedix Prices $25 Million Share Offering	Nov. 16	MT

Chart Augmedix, Inc.

Duration

Period

More charts

Company Profile

Augmedix, Inc. helps clinicians and patients form a human connection at the point of care. The Company uses its proprietary Notebuilder Platform to automate the note creation process, aided by its trained MDSs. It also provides data services associated with these products, which include aggregated structured data and metadata associated with medical notes. Its products include Augmedix Live, Augmedix Notes, Augmedix Prep and Augmedix Go. Augmedix Live provides synchronous medical note documentation and point of care support. Augmedix Notes provides asynchronous medical documentation based upon previously recorded visit. Prep provides chart preparation delivered prior to the patient visit. Prep transfers patient demographics, past medical history, medication changes and other key data points from the patientâs health to the current visit note. Clinicians access its products and service through mobile devices, managed by it or their health enterprise.

Sector

Business Support Services

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Augmedix, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.85 USD

Average target price

6.1 USD

Spread / Average Target

+114.04%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Business Support Services

	1st Jan change	Capi.
AUGMEDIX, INC.	-51.28%	139M
CINTAS CORPORATION	+10.55%	67.6B
JACOBS SOLUTIONS INC.	+11.64%	18.21B
BUREAU VERITAS SA	+21.03%	13.41B
RB GLOBAL, INC.	+9.40%	13.37B
INTERTEK GROUP PLC	+16.53%	9.94B
TELEPERFORMANCE SE	-32.90%	5.74B
GENPACT LIMITED	-10.98%	5.57B
MAXIMUS, INC.	-4.09%	4.91B
EXLSERVICE HOLDINGS, INC.	-4.83%	4.87B

Other Business Support Services

Augmedix, Inc.

Equities

AUGX

US05105P1075

Business Support Services

Augmedix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

EPS Revisions